| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| NEURIZON THERAPEUTICS Aktie jetzt für 0€ handeln | |||||
| Fr | Neurizon, Elanco Ink Long-Term Supply Agreement for Human Health Monepantel | 2 | Contract Pharma | ||
| Fr | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | - | ASX | ||
| Mi | Daily Special: Aerometrex, Neurizon, Norwood | 1 | Finance News Network | ||
| Mi | NEURIZON THERAPEUTICS LIMITED: Neurizon executes long-term supply agreement with Elanco | 1 | ASX | ||
| 12.06. | NEURIZON THERAPEUTICS LIMITED: HEALEY ALS Trial Surpasses 50% Dosing Ahead of Schedule | 1 | ASX | ||
| 02.06. | Biocurious: Ahead of this year's Big Freeze, Neurizon hopes to 'do it for Daniher' | 3 | Stockhead | ||
| 02.06. | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | 4 | ASX | ||
| 28.05. | NEURIZON THERAPEUTICS LIMITED: Webinar presentation - Regimen I expands to 240 participants | 1 | ASX | ||
| 27.05. | Wednesday's HotCopper trends: Lodestar, Minbos, Neurizon, and other daily topics | 8 | The Market Online Australia | ||
| 27.05. | NEURIZON THERAPEUTICS LIMITED: HEALEY ALS Trial Regimen I Expands to 240 Participants | 1 | ASX | ||
| 13.05. | Neurizon Therapeutics Gains Ethics Approval for NUZ-001 Oral Liquid Phase 1 Study | 6 | smallcaps.com.au | ||
| 13.05. | NEURIZON THERAPEUTICS LIMITED: Ethics Approval Received for NUZ-001 Oral Liquid P1 Study | - | ASX | ||
| 12.05. | NEURIZON THERAPEUTICS LIMITED: Final Director's Interest Notice | 2 | ASX | ||
| 12.05. | NEURIZON THERAPEUTICS LIMITED: Initial Director's Interest Notice | - | ASX | ||
| 11.05. | NEURIZON THERAPEUTICS LIMITED: Australian Microcap Investment Conference Presentation | 4 | ASX | ||
| 08.05. | NEURIZON THERAPEUTICS LIMITED: Neurizon Strengthens Board for the Next Growth Phase | 1 | ASX | ||
| 04.05. | NEURIZON THERAPEUTICS LIMITED: Change of Director's Interest Notices | - | ASX | ||
| 30.04. | NEURIZON THERAPEUTICS LIMITED: Neurizon investor briefing presentation | 2 | ASX | ||
| 30.04. | NEURIZON THERAPEUTICS LIMITED: Application for quotation of securities - NUZ | - | ASX | ||
| 30.04. | NEURIZON THERAPEUTICS LIMITED: Appendix 4C & Quarterly Update | 1 | ASX |
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| PFIZER | 21,960 | -0,95 % | Pfizer-Finanzchef geht im August | NEW YORK (dpa-AFX) - Pfizer steht vor einem Wechsel im Finanzressort. Wie der US-Pharmakonzern am Donnerstag in New York mitteilte, wird Finanzvorstand Dave Denton sein Amt zum 15. August niederlegen... ► Artikel lesen | |
| NOVARTIS | 130,10 | +1,39 % | Milliarden-Übernahmen, Kapitalmangel und Stammzelltherapien: Warum Mesoblast in einem spannenden Marktumfeld agiert | ||
| GILEAD SCIENCES | 108,48 | +0,63 % | Dividendenbekanntmachungen (15.06.2026) | Unternehmen ISIN-Code Dividende (Währung) Dividende (EUR) A&W FOOD SERVICES OF CANADA INC CA0002251027 0,48 CAD 0,2966 EUR AEGON LTD ADR US0076CA1045 0,2468 USD 0,2134 EUR AGROB IMMOBILIEN... ► Artikel lesen | |
| ROCHE | 344,68 | +0,19 % | Roche Reports FDA Filing Acceptance For Lunsumio VELO, Polivy Combination | SOUTH SAN FRANCISCO (dpa-AFX) - Roche (RHHBY, RO.SW, ROG.SW) announced the FDA has accepted the company's supplemental Biologics License Application for Lunsumio VELO, as a subcutaneous formulation... ► Artikel lesen | |
| STADA ARZNEIMITTEL | - | - | Enzymatica AB: Quarterly report Q1/2026 - Enzymatica strengthens international position through STADA agreement | First quarter
Net sales amounted to SEK 11.4 million (12.3).
Operating result amounted to SEK -13.6.million (-18.0)
Earnings per share, before... ► Artikel lesen | |
| TEVA | 27,500 | -2,48 % | Teva Pharmaceutical Industries Ltd: Teva Releases Q2 2026 Aide Memoire | TEL AVIV, Israel, June 18, 2026 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA) announced today that its Q2 2026 Aide Memoire is available on the "Investors" page on its... ► Artikel lesen | |
| DIGICANN VENTURES | 0,006 | +10,00 % | XFRA VY3: WIEDERAUFNAHME/RESUMPTION | FOLGENDE(S) INSTRUMENT(E) WIRD/ WERDEN WIEDER IN DEN HANDEL AUFGENOMMEN MIT FOLGENDEM TRADING SCHEDULE.THE FOLLOWING INSTRUMENT(S) IS/ARE RESUMED TRADING WITH FOLLOWING TRADING SCHEDULE:INSTRUMENT NAME... ► Artikel lesen | |
| EYEPOINT | 11,900 | +0,85 % | EyePoint Aktionäre genehmigen Incentive-Plan und wählen Direktoren | ||
| GREEN THUMB INDUSTRIES | 6,570 | -1,50 % | Green Thumb Industries Inc. - 8-K, Current Report | ||
| IONIS PHARMACEUTICALS | 64,20 | 0,00 % | XETR NEW INSTRUMENTS AVAILABLE ON XETRA - 04.06.2026 | Folgende Wertpapiere werden in den Handel an folgenden Handelsplätzen (MIC Code) im Quotation Board an der Frankfurter Wertpapierbörse (FWB) aufgenommen. Die Notierung an anderen Handelsplätzen im Quotation... ► Artikel lesen | |
| SINOPHARM | 1,830 | -1,43 % | SINOPHARM (01099): PROPOSED DISTRIBUTION OF FINAL DIVIDEND AND CLOSURE OF REGISTER OF MEMBERS (UPDATED) | ||
| ASSEMBLY BIOSCIENCES | 21,700 | +1,88 % | Assembly Biosciences-Aktie: "Phänomenale" Daten und "Big Catalyst" voraus | Für langjährige Beobachter von Assembly Biosciences war 2025 ein Jahr der Validierung. Auf der Goldman Sachs Healthcare Conference 2026 machte CEO Jason Okazaki gestern deutlich, warum das Unternehmen... ► Artikel lesen | |
| CSPC PHARMA | 0,769 | -2,18 % | CSPC PHARMA (01093): FURTHER ANNOUNCEMENT - UPDATE ON DISCLOSEABLE TRANSACTION IN RELATION TO THE PROPOSED H SHARE LISTING OF CSPC INNOVATION | ||
| ALNYLAM PHARMACEUTICALS | 245,80 | +1,61 % | Alnylam (ALNY) Expands Its RNAi Therapeutics Reach Into Four More Nordic Countries | ||
| NEKTAR THERAPEUTICS | 56,38 | +2,92 % | NEKTAR THERAPEUTICS - 8-K, Current Report |